Hemophilia: From Pathophysiology to Novel Therapies

Dear Colleagues,

Hemophilia is the most common X-linked congenital bleeding disorder in humans, caused by the deficiency or dysfunction of factor VIII or factor IX. The mainstay of treatment and current standard of care for hemophilia is regular prophylaxis with the administration of factor VIII/IX, mimics of clotting factors, and coagulation rebalancing agent; gene therapy is also used. We notice that most authors, physicians, and scientists devote themselves to clinical trials of these new therapeutic agents. Very few physicians are interested in and pay attention to how these new agents are created; the pathogenesis of hemophilia is even less studied. However, the latter is more fundamental and will be more instructive to young researchers, although treatments for hemophilia and the achievement of better quality of life are important. We would like to invite and encourage researchers to submit articles focusing on the development of novel therapies in hemophilia, the evolution from basic science to clinical translation, and molecular studies on the pathogenesis of hemophilia.

Prof. Dr. Mingching Shen
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.